Citadel Advisors
CHRS icon

Citadel Advisors’s Coherus Oncology CHRS Stock Holding History

Citadel Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Sell
115,800
-5,200
-4% -$8.49K ﹤0.01% 12280
2026
Q1 		$204K Buy
121,000
+100,000
+476% +$178K ﹤0.01% 11371
2025
Q4 		$29.8K Sell
21,000
-98,700
-82% -$144K ﹤0.01% 12226
2025
Q3 		$196K Buy
119,700
+88,700
+286% +$98.7K ﹤0.01% 11285
2025
Q2 		$22.7K Sell
31,000
-34,300
-53% -$29.6K ﹤0.01% 12077
2025
Q1 		$52.7K Sell
65,300
-26,500
-29% -$30.5K ﹤0.01% 12262
2024
Q4 		$127K Buy
91,800
+52,300
+132% +$58.7K ﹤0.01% 11111
2024
Q3 		$41.1K Sell
39,500
-11,400
-22% -$15.6K ﹤0.01% 12122
2024
Q2 		$88.1K Sell
50,900
-34,700
-41% -$69.8K ﹤0.01% 11095
2024
Q1 		$205K Sell
85,600
-38,384
-31% -$94.5K ﹤0.01% 10279
2023
Q4 		$413K Buy
123,984
+69,684
+128% +$187K ﹤0.01% 8502
2023
Q3 		$203K Buy
54,300
+14,100
+35% +$65.1K ﹤0.01% 9883
2023
Q2 		$172K Buy
40,200
+32,600
+429% +$192K ﹤0.01% 10119
2023
Q1 		$52K Sell
7,600
-31,400
-81% -$244K ﹤0.01% 12097
2022
Q4 		$309K Buy
+39,000
New +$300K ﹤0.01% 9254
2021
Q4 		– Sell
-14,100
Closed -$227K – 13860
2021
Q3 		$227K Sell
14,100
-11,200
-44% -$164K ﹤0.01% 11700
2021
Q2 		$350K Buy
25,300
+400
+2% +$5.67K ﹤0.01% 10890
2021
Q1 		$364K Buy
24,900
+9,800
+65% +$166K ﹤0.01% 10394
2020
Q4 		$262K Buy
+15,100
New +$269K ﹤0.01% 9298
2020
Q2 		– Sell
-10,300
Closed -$167K – 9834
2020
Q1 		$167K Sell
10,300
-5,300
-34% -$97.9K ﹤0.01% 8185
2019
Q4 		$281K Buy
15,600
+5,600
+56% +$103K ﹤0.01% 7680
2019
Q3 		$203K Sell
10,000
-1,900
-16% -$38K ﹤0.01% 8134
2019
Q2 		$263K Buy
+11,900
New +$207K ﹤0.01% 7783
2019
Q1 		– Sell
-17,100
Closed -$155K – 9300
2018
Q4 		$155K Sell
17,100
-2,700
-14% -$31.2K ﹤0.01% 8035
2018
Q3 		$327K Buy
+19,800
New +$351K ﹤0.01% 7428
2017
Q3 		– Sell
-11,500
Closed -$165K – 7568
2017
Q2 		$165K Buy
+11,500
New +$221K ﹤0.01% 6674

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Citadel Advisors's CHRS Position: Q2 2026 in Review

Citadel Advisors reduced its Coherus Oncology (CHRS) stake by 82% in Q2 2026, selling an estimated $313K and leaving 42,111 shares worth $59K. The position accounts for ﹤0.01% of the portfolio, ranked #13048.

Citadel Advisors first reported a position in CHRS in Q1 2015 and has held it in 39 quarters since. The position peaked at $34.3M in Q1 2019. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Citadel Advisors held 42,111 shares of Coherus Oncology worth $59K as of Q2 2026.
  • Citadel Advisors sold 191,835 Coherus Oncology shares in Q2 2026, an estimated $313K.
  • Coherus Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13048 holding.
  • Citadel Advisors first reported a position in Coherus Oncology in Q1 2015 and has held it in 39 quarters since.
  • Citadel Advisors's Coherus Oncology position peaked at $34.3M in Q1 2019.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.